Koers VG Life Sciences Inc. Other OTC
Aandelen
VGLS
US91822T1016
Biotechnologie & Medisch Onderzoek
Omzet 2013 | - | Omzet 2014 | - | Marktkapitalisatie | 2,23 mln. 2,08 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -7 mln. -6,55 mln. | Nettowinst (verlies) 2014 | -6 mln. -5,62 mln. | EV/omzet 2013 | - |
Nettoschuld 2013 | 2,49 mln. 2,33 mln. | Nettoschuld 2014 | 3,83 mln. 3,58 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-0,25
x | K/w-verhouding 2014 |
-0,31
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Ana Gois
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+31,01% | 52,73 mld. | |
+37,49% | 39 mld. | |
-9,14% | 38,52 mld. | |
+28,05% | 30,38 mld. | |
-12,26% | 26,39 mld. | |
+11,61% | 26,08 mld. | |
+45,23% | 14,15 mld. | |
+33,03% | 12,6 mld. | |
-5,38% | 11,51 mld. |